Healthcare provider profile · identity verified

Michael Sarai, DO

Internal Medicine · BELLINGHAM, WA · NPI 1184128944

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	359	132
Levothyroxine Sodium	Levothyroxine Sodium	284	90
Amlodipine Besylate	Amlodipine Besylate	202	81
Losartan Potassium	Losartan Potassium	139	53
Omeprazole	Omeprazole	136	49
Metoprolol Succinate	Metoprolol Succinate	125	41
Pantoprazole Sodium	Pantoprazole Sodium	121	52
Lisinopril	Lisinopril	120	49
Rosuvastatin Calcium	Rosuvastatin Calcium	120	48
Gabapentin	Gabapentin	116	41
Oxycodone Hcl	Oxycodone Hcl	90	47
Pravastatin Sodium	Pravastatin Sodium	79	34
Sertraline Hcl	Sertraline Hcl	78	19
Eliquis	Apixaban	74	27
Trazodone Hcl	Trazodone Hcl	73	28
Hydrochlorothiazide	Hydrochlorothiazide	70	32
Simvastatin	Simvastatin	69	25
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	68	32
Tamsulosin Hcl	Tamsulosin Hcl	66	28
Fluticasone Propionate	Fluticasone Propionate	65	39
Duloxetine Hcl	Duloxetine Hcl	58	21
Tramadol Hcl	Tramadol Hcl	53	21
Alendronate Sodium	Alendronate Sodium	52	20
Citalopram Hbr	Citalopram Hydrobromide	52	18
Metoprolol Tartrate	Metoprolol Tartrate	50	17
Clonazepam	Clonazepam	47	12
Venlafaxine Hcl Er	Venlafaxine Hcl	46	11
Carvedilol	Carvedilol	45	18
Pregabalin	Pregabalin	45	15
Albuterol Sulfate Hfa	Albuterol Sulfate	44	23
Furosemide	Furosemide	44	26
Prednisone	Prednisone	44	27
Buspirone Hcl	Buspirone Hcl	43	13
Metformin Hcl	Metformin Hcl	43	17
Lorazepam	Lorazepam	42	14
Metformin Hcl Er	Metformin Hcl	40	17
Potassium Chloride	Potassium Chloride	39	17
Olmesartan Medoxomil	Olmesartan Medoxomil	37	13
Montelukast Sodium	Montelukast Sodium	36	11
Allopurinol	Allopurinol	35	16
Famotidine	Famotidine	35	13
Clopidogrel	Clopidogrel Bisulfate	32	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	11
Mirtazapine	Mirtazapine	31	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	27	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	25	11
Atenolol	Atenolol	24	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Lamotrigine	Lamotrigine	23	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	22	suppressed
Finasteride	Finasteride	21	suppressed
Synthroid	Levothyroxine Sodium	21	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	20	19
Nystatin	Nystatin	20	15
Xarelto	Rivaroxaban	20	suppressed
Baclofen	Baclofen	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	12
Warfarin Sodium	Warfarin Sodium	19	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	12
Aripiprazole	Aripiprazole	17	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	16	suppressed
Estradiol	Estradiol	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Celecoxib	Celecoxib	15	14
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Olanzapine	Olanzapine	15	suppressed
Torsemide	Torsemide	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Cephalexin	Cephalexin	14	13
Glimepiride	Glimepiride	14	suppressed
Nitroglycerin	Nitroglycerin	14	12
Donepezil Hcl	Donepezil Hcl	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Alprazolam	Alprazolam	12	suppressed
Ramipril	Ramipril	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Donepezil Hcl Odt	Donepezil Hcl	11	suppressed
Epinephrine	Epinephrine	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error